{
    "ticker": "IDYA",
    "name": "Ideaya Biosciences, Inc.",
    "description": "Ideaya Biosciences, Inc. is a biotechnology company focused on the discovery and development of targeted therapeutics for cancer and other genetic diseases. Founded in 2010 and headquartered in South San Francisco, California, Ideaya aims to address significant unmet medical needs by employing a precision medicine approach. The company is committed to developing innovative therapies that target specific genetic and molecular drivers of disease. Ideaya's product pipeline includes multiple clinical and preclinical programs, with a focus on synthetic lethality and other targeted mechanisms. The company's lead product candidate, IDE196, is an investigational therapy designed to treat patients with GNAQ or GNA11 mutant tumors. Ideaya collaborates with leading academic institutions and pharmaceutical companies to advance its research and accelerate the development of its drug candidates. With a strong emphasis on scientific rigor and collaboration, Ideaya is dedicated to improving patient outcomes and advancing the field of precision oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2010",
    "website": "https://www.ideayabio.com",
    "ceo": "Susan M. Galbraith",
    "social_media": {
        "twitter": "https://twitter.com/IdeayaBio",
        "linkedin": "https://www.linkedin.com/company/ideaya-biosciences"
    },
    "investor_relations": "https://investors.ideayabio.com",
    "key_executives": [
        {
            "name": "Susan M. Galbraith",
            "position": "CEO"
        },
        {
            "name": "Mark V. D. R. Leung",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "IDE196",
                "IDE161"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ideaya Biosciences, Inc. | Precision Oncology and Targeted Therapeutics",
        "meta_description": "Discover Ideaya Biosciences, Inc., a leader in precision medicine focused on targeted therapeutics for cancer. Explore their innovative drug development pipeline and commitment to improving patient outcomes.",
        "keywords": [
            "Ideaya Biosciences",
            "Biotechnology",
            "Precision Medicine",
            "Cancer Therapy",
            "Targeted Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does Ideaya Biosciences focus on?",
            "answer": "Ideaya Biosciences focuses on the discovery and development of targeted therapeutics for cancer and genetic diseases."
        },
        {
            "question": "Who is the CEO of Ideaya Biosciences?",
            "answer": "Susan M. Galbraith is the CEO of Ideaya Biosciences, Inc."
        },
        {
            "question": "Where is Ideaya Biosciences headquartered?",
            "answer": "Ideaya Biosciences is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are Ideaya's main products?",
            "answer": "Ideaya's main product candidates include IDE196 and IDE161."
        },
        {
            "question": "When was Ideaya Biosciences founded?",
            "answer": "Ideaya Biosciences was founded in 2010."
        }
    ],
    "competitors": [
        "NVTA",
        "CRSP",
        "EDIT",
        "SGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}